1-20 of 93
Adam D. Cohen
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Impact of soluble BCMA and non-T-cell factors on refractoriness to BCMA-targeting T-cell engagers in multiple myeloma

Holly Lee, Michael A. Durante, Sheri Skerget, Deeksha Vishwamitra, Sacha Benaoudia, Sungwoo Ahn, Mansour Poorebrahim, Elie Barakat, David Jung, Noémie Leblay, Bachisio Ziccheddu, Benjamin T. Diamond, Marios Papadimitriou, Adam D. Cohen, Ola Landgren, Paola Neri, Francesco Maura, Nizar J. Bahlis
Journal: Blood
Blood blood.2024026212.
https://doi.org/10.1182/blood.2024026212
Published: 2024
Includes: Supplemental data
Journal Articles

Safety and Efficacy of Teclistamab in Patients with Relapsed or Refractory AL Amyloidosis: A Retrospective Case Series

Margaret Stalker, Alfred L. Garfall, Adam D. Cohen, Dan T. Vogl, Sandra Susanibar-Adaniya, Mia Djulbegovic, Edward A. Stadtmauer, Oxana Megherea, Adam Waxman
Journal: Blood
Blood (2023) 142 (Supplement 1): 2035.
https://doi.org/10.1182/blood-2023-189277
Published: 2023
Journal Articles

A Randomized Controlled Trial of a Financial Navigation Program for Patients with Multiple Myeloma

Mia Djulbegovic, Meredith Doherty, Katie Fanslau, Kan Chen, Sarah Girgis, Pearl Joslyn, Shawn Carney, Joyce Mitchell, Abbie Etzweiler, Dan T. Vogl, Adam D. Cohen, Alfred L. Garfall, Adam Waxman, Sandra Susanibar-Adaniya, Zachary AK Frosch, Qi Long, Karen Glanz, Edward A. Stadtmauer
Journal: Blood
Blood (2023) 142 (Supplement 1): 909.
https://doi.org/10.1182/blood-2023-174451
Published: 2023
Journal Articles

Sequential T-Cell Engagement for Myeloma (“STEM”) Trial: A Phase 2 Study of Cevostamab Consolidation Following BCMA CAR T Cell Therapy

Adam D. Cohen, Wei-Ting Hwang, Sandra Susanibar-Adaniya, Dan T. Vogl, Alfred L. Garfall, Adam Waxman, Danielle Zubka, Chau Nguyen, Cynthia Diaczynsky, Marco Ruella, Michael C. Milone, Edward A. Stadtmauer
Journal: Blood
Blood (2023) 142 (Supplement 1): 3389.
https://doi.org/10.1182/blood-2023-187409
Published: 2023
Journal Articles

Heterogeneity in Access and Toxicity Management of Commercially Available BCMA-Directed CAR-T and Bispecific T-Cell Engager Therapy Among the International Myeloma Community

Hamza Hassan, Mehmet K. Samur, Adam D. Cohen, Philippe Moreau, Paula Rodríguez Otero, Shaji Kunnathu Kumar, María Victoria Mateos, David Avigan, Adam S. Sperling, Omar Nadeem, Michael Hudecek, Carlos Fernández de Larrea, Joaquin Martínez-López, Maria Themeli, Kwee Yong, Jesus G. Berdeja, Ajai Chari, Pieter Sonneveld, Francesca Gay, Amrita Krishnan, Saad Z Usmani, Kenneth C. Anderson, Sundar Jagannath, Hermann Einsele, Nikhil C Munshi, Shonali Midha
Journal: Blood
Blood (2023) 142 (Supplement 1): 7248.
https://doi.org/10.1182/blood-2023-184710
Published: 2023
Journal Articles

A Phase 2, Single-Arm, Non-Inferiority Study of Limited-Duration Teclistamab for Relapsed and Refractory Multiple Myeloma (LimiTec)

Beatrice Razzo, Connor Grady, Sandra Susanibar-Adaniya, Adam Waxman, Dan T. Vogl, Adam D. Cohen, Edward A. Stadtmauer, Wei-Ting Hwang, Alfred L. Garfall
Journal: Blood
Blood (2023) 142 (Supplement 1): 3394.
https://doi.org/10.1182/blood-2023-177735
Published: 2023
Journal Articles

Biomarker Correlates of Response to Ciltacabtagene Autoleucel in Patients with Relapsed or Refractory Multiple Myeloma from CARTITUDE-1, a Phase 1b/2 Open-Label Study, at the ~3 Year Follow-up

Rocio Montes de Oca, Junchen Gu, Hao Zhao, Kathy Zelinsky, Dianna Wu, Cuc Davis, Jaymala Patel, Brad Foulk, Rengasamy Boominathan, Onsay Lau, Denis Smirnov, Yi Lin, Sundar Jagannath, Adam D. Cohen, Nahor Haddish-Berhane, Jean Xu, Deepu Madduri, An-Sofie Stevens, Carolyn Chang Jackson, Jordan M. Schecter, Arnob Banerjee, Dong Geng, Jieqing Zhu, Sifan Xu, Enrique Zudaire
Journal: Blood
Blood (2023) 142 (Supplement 1): 2099.
https://doi.org/10.1182/blood-2023-182298
Published: 2023
Journal Articles

The Phase 2 CARTITUDE-2 Trial: Updated Efficacy and Safety of Ciltacabtagene Autoleucel in Patients with Multiple Myeloma and 1-3 Prior Lines of Therapy (Cohort A) and with Early Relapse after First Line Treatment (Cohort B)

Jens Hillengass, Adam D. Cohen, Mounzer E Agha, Michel Delforge, Tessa Kerre, Wilfried Roeloffzen, Hermann Einsele, Hartmut Goldschmidt, Katja Weisel, Marc S. Raab, Christof Scheid, Sebastien Anguille, Pieter Sonneveld, Sonja Zweegman, Jordan M. Schecter, Kevin C De Braganca, Carolyn Chang Jackson, Philip Vlummens, Helen Varsos, Christina Corsale, Deepu Madduri, Tzu-min Yeh, Pankaj Mistry, Tito Roccia, Qingxuan Song, Muhammad Akram, Octavio Costa Filho, Dong Geng, Yael C. Cohen, Niels W.C.J. Van De Donk
Journal: Blood
Blood (2023) 142 (Supplement 1): 1021.
https://doi.org/10.1182/blood-2023-178882
Published: 2023
Journal Articles

Impact of Psychological Distress on Immune Phenotype in CLL/SLL Patients Managed By Active Observation

Carolyn Y. Fang, Jakub Svoboda, Adam D. Cohen, Henry C. Fung, Richard I. Fisher, Elizabeth Handorf, Hatcher Ballard, Stefan K. Barta, Daniel J. Landsburg, Dwivedy S. Nasta, Stephen J Schuster, Rashmi Khanal, Alexander W. MacFarlane, Kerry S. Campbell
Journal: Blood
Blood (2023) 142 (Supplement 1): 6526.
https://doi.org/10.1182/blood-2023-189330
Published: 2023
Journal Articles

Birtamimab plus standard of care in light-chain amyloidosis: the phase 3 randomized placebo-controlled VITAL trial

Clinical Trials & Observations
Morie A. Gertz, Adam D. Cohen, Raymond L. Comenzo, Efstathios Kastritis, Heather J. Landau, Edward N. Libby, Michaela Liedtke, Vaishali Sanchorawala, Stefan Schönland, Ashutosh Wechalekar, Jeffrey A. Zonder, Giovanni Palladini, Jackie Walling, Spencer Guthrie, Christie Nie, Carol Karp, Yuying Jin, Gene G. Kinney, Giampaolo Merlini
Journal: Blood
Blood (2023) 142 (14): 1208–1218.
https://doi.org/10.1182/blood.2022019406
Published: 2023
Includes: Supplemental data
Journal Articles

Efficacy and safety of cilta-cel in patients with progressive multiple myeloma after exposure to other BCMA-targeting agents

Clinical Trials & Observations
Adam D. Cohen, María-Victoria Mateos, Yael C. Cohen, Paula Rodriguez-Otero, Bruno Paiva, Niels W. C. J. van de Donk, Thomas Martin, Attaya Suvannasankha, Kevin C. De Braganca, Christina Corsale, Jordan M. Schecter, Helen Varsos, William Deraedt, Liwei Wang, Martin Vogel, Tito Roccia, Xiaoying Xu, Pankaj Mistry, Enrique Zudaire, Muhammad Akram, Tonia Nesheiwat, Lida Pacaud, Irit Avivi, Jesus San-Miguel
Journal: Blood
Blood (2023) 141 (3): 219–230.
https://doi.org/10.1182/blood.2022015526
Published: 2023
Includes: Supplemental data
Journal Articles

Phase 2 Study of Belantamab Mafodotin As Pre- and Post-Stem Cell Transplant Consolidation and Maintenance (BLAST study) for Multiple Myeloma Patients in First Remission

Adam D Cohen, Alfred L Garfall, Sandra Patricia Susanibar-Adaniya, Dan T. Vogl, Adam Waxman, Oksana De Mesa, Elizabeth Kane, Charles Nichols, Beatrice Razzo, Edward A. Stadtmauer
Journal: Blood
Blood (2022) 140 (Supplement 1): 12628–12629.
https://doi.org/10.1182/blood-2022-165526
Published: 2022
Journal Articles

Efficacy and Safety of Cilta-Cel in Patients with Progressive Multiple Myeloma after Exposure to Non-Cellular Anti-BCMA Immunotherapy

Adam D. Cohen, María-Victoria Mateos, Yael C. Cohen, Paula Rodriguez Otero, Bruno Paiva, Niels W.C.J. Van De Donk, Thomas Martin, Attaya Suvannasankha, Christina Corsale, Jordan M. Schecter, Kevin C. De Braganca, Carolyn C. Jackson, Helen Varsos, William Deraedt, Tito Roccia, Pankaj Mistry, Xiaoying Xu, Katherine Li, Enrique Zudaire, Muhammad Akram, Lida Pacaud, Irit Avivi, Jesús San-Miguel
Journal: Blood
Blood (2022) 140 (Supplement 1): 4646–4648.
https://doi.org/10.1182/blood-2022-158563
Published: 2022
Journal Articles

Infectious Complications of B-Cell Maturation Antigen (BCMA)-Targeted Therapies for Relapsed/Refractory Multiple Myeloma

Brian Hoeynck, Wei-Ting Hwang, Alfred L Garfall, Sandra Patricia Susanibar-Adaniya, Dan T. Vogl, Adam Waxman, Edward A. Stadtmauer, Adam D Cohen
Journal: Blood
Blood (2022) 140 (Supplement 1): 10081–10083.
https://doi.org/10.1182/blood-2022-165650
Published: 2022
Journal Articles

Enduring Responses after 1-Year, Fixed-Duration Cevostamab Therapy in Patients with Relapsed/Refractory Multiple Myeloma: Early Experience from a Phase I Study

Alexander M Lesokhin, Joshua Richter, Suzanne Trudel, Adam D Cohen, Andrew Spencer, Peter A Forsberg, Jacob P Laubach, Sheeba K Thomas, Nizar J. Bahlis, Luciano J. Costa, Paula Rodriguez Otero, Maria-Victoria Mateos, Jesus G Berdeja, Rayan Kaedbey, Amrita Y. Krishnan, Rafael Fonseca, Voleak Choeurng, James Cooper, Teiko Sumiyoshi, Chihunt Wong, Simon J Harrison
Journal: Blood
Blood (2022) 140 (Supplement 1): 4415–4417.
https://doi.org/10.1182/blood-2022-157547
Published: 2022
Journal Articles

Ciltacabtagene Autoleucel (Cilta-cel), a BCMA-Directed CAR-T Cell Therapy, in Patients with Multiple Myeloma (MM) and Early Relapse after Initial Therapy: CARTITUDE-2 Cohort B 18-Month Follow-up

Niels WCJ Van De Donk, Mounzer Agha, Adam D Cohen, Yael C Cohen, Sébastien Anguille, Tessa Kerre, Wilfried W.H. Roeloffzen, Jordan M Schecter, Kevin C De Braganca, Carolyn C Jackson, Helen Varsos, Pankaj Mistry, Tito Roccia, Xiaoying Xu, Katherine Li, Enrique Zudaire, Christina Corsale, Muhammad Akram, Dong Geng, Lida Pacaud, Pieter Sonneveld, Sonja Zweegman
Journal: Blood
Blood (2022) 140 (Supplement 1): 7536–7537.
https://doi.org/10.1182/blood-2022-159169
Published: 2022
Journal Articles

Renal Toxicity with Carfilzomib in Multiple Myeloma: Secondary Analysis of SWOG S1304 Comparing Low-Dose Versus High-Dose Carfilzomib

Rajshekhar Chakraborty, Rachael Sexton, Suzanne Lentzsch, Muneer H. Abidi, Peter M. Voorhees, Adam D Cohen, Eric Rohren, Stephen B. Heitner, Kevin R. Kelly, Niklas J Mackler, David M. Baer, Antje Hoering, Brian G.M. Durie, Sikander Ailawadhi, Robert Z. Orlowski
Journal: Blood
Blood (2022) 140 (Supplement 1): 4349–4351.
https://doi.org/10.1182/blood-2022-166609
Published: 2022
Journal Articles

Efficacy Outcomes and Characteristics of Patients with Multiple Myeloma (MM) Who Achieved Sustained Minimal Residual Disease Negativity after Treatment with Ciltacabtagene Autoleucel (cilta-cel) in CARTITUDE-1

Nikhil C. Munshi, Bruno Paiva, Thomas Martin, Saad Usmani, Yi Lin, Jordan M. Schecter, Carolyn C. Jackson, Deepu Madduri, Enrique Zudaire, Tzu-min Yeh, J. Blake Bartlett, Lida Pacaud, Muhammad Akram, Dong Geng, Sundar Jagannath, Adam D. Cohen, Jesús San-Miguel
Journal: Blood
Blood (2022) 140 (Supplement 1): 4652–4654.
https://doi.org/10.1182/blood-2022-159141
Published: 2022
Journal Articles

Total Car-T Cost of Care Beyond the Price of Car-T Cell Therapy in Patients with Multiple Myeloma

Sundar Jagannath, Nedra Joseph, Concetta Crivera, Carolyn C. Jackson, Satish Valluri, Patricia Cost, Hilary Phelps, Rafal Slowik, Timothy Klein, Xueting Yu, Lee Smolen, Adam D Cohen
Journal: Blood
Blood (2021) 138 (Supplement 1): 4964.
https://doi.org/10.1182/blood-2021-153438
Published: 2021
Journal Articles

Updated Results from CARTITUDE-1: Phase 1b/2Study of Ciltacabtagene Autoleucel, a B-Cell Maturation Antigen-Directed Chimeric Antigen Receptor T Cell Therapy, in Patients With Relapsed/Refractory Multiple Myeloma

Thomas Martin, Saad Z. Usmani, Jesús G. Berdeja, Andrzej Jakubowiak, Mounzer Agha, Adam D Cohen, Parameswaran Hari, David Avigan, Abhinav Deol, Myo Htut, Alexander Lesokhin, Nikhil C. Munshi, Elizabeth O'Donnell, A. Keith Stewart, Jordan M. Schecter, Jenna D. Goldberg, Carolyn C. Jackson, Tzu-Min Yeh, Arnob Banerjee, Alicia Allred, Enrique Zudaire, William Deraedt, Deepu Madduri, Yunsi Olyslager, Changwei Zhou, Lida Pacaud, Yi Lin, Sundar Jagannath
Journal: Blood
Blood (2021) 138 (Supplement 1): 549.
https://doi.org/10.1182/blood-2021-146060
Published: 2021